Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, Aster JC, Kuo F, Huang D, Lira PD, McLachlan KR, Kern KA, Garcia-Manero G, Martinelli G.

Blood Cancer J. 2015 Sep 25;5:e350. doi: 10.1038/bcj.2015.80. No abstract available.

2.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA.

Int J Cancer. 2016 Jan 1;138(1):195-205. doi: 10.1002/ijc.29676. Epub 2015 Jul 22.

3.

PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.

Wang K, Zhang Q, Li D, Ching K, Zhang C, Zheng X, Ozeck M, Shi S, Li X, Wang H, Rejto P, Christensen J, Olson P.

Clin Cancer Res. 2015 Mar 15;21(6):1487-96. doi: 10.1158/1078-0432.CCR-14-1348. Epub 2015 Jan 6.

4.

HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.

Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z, Zhang C, Chen X, Chen KX, Li J, Chen SH, Christensen J, Mao M, Chan CC.

J Thorac Oncol. 2014 Mar;9(3):285-94. doi: 10.1097/JTO.0000000000000087.

5.

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.

J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.

PMID:
24418728
6.

Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).

Pavlicek A, Lira ME, Lee NV, Ching KA, Ye J, Cao J, Garza SJ, Hook KE, Ozeck M, Shi ST, Yuan J, Zheng X, Rejto PA, Kan JL, Christensen JG.

Mol Cancer Ther. 2013 Dec;12(12):2929-39. doi: 10.1158/1535-7163.MCT-13-0442-T. Epub 2013 Oct 9.

7.

Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.

Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG.

Clin Cancer Res. 2012 Sep 15;18(18):5008-19. doi: 10.1158/1078-0432.CCR-12-1379. Epub 2012 Jul 17.

8.

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, Yuan J, Ye J, Ozeck M, Shi ST, Zheng X, Rejto PA, Kan JL, Christensen JG, Pavlicek A.

Mol Cancer Ther. 2012 Mar;11(3):710-9. doi: 10.1158/1535-7163.MCT-11-0184. Epub 2012 Jan 5.

9.

Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways.

Ozeck M, Brust P, Xu H, Servant G.

Eur J Pharmacol. 2004 Apr 12;489(3):139-49.

PMID:
15087236
10.

Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF).

Palle VP, Varkhedkar V, Ibrahim P, Ahmed H, Li Z, Gao Z, Ozeck M, Wu Y, Zeng D, Wu L, Leung K, Chu N, Zablocki JA.

Bioorg Med Chem Lett. 2004 Jan 19;14(2):535-9.

PMID:
14698198
12.

Tonic activity of the rat adipocyte A1-adenosine receptor.

Liang HX, Belardinelli L, Ozeck MJ, Shryock JC.

Br J Pharmacol. 2002 Mar;135(6):1457-66.

13.

Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells.

Grant MB, Tarnuzzer RW, Caballero S, Ozeck MJ, Davis MI, Spoerri PE, Feoktistov I, Biaggioni I, Shryock JC, Belardinelli L.

Circ Res. 1999 Oct 15;85(8):699-706.

PMID:
10521243
14.
15.

LU 51198, a highly sulfated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused rabbit heart.

Gralinski MR, Park JL, Ozeck MA, Wiater BC, Lucchesi BR.

J Pharmacol Exp Ther. 1997 Aug;282(2):554-60.

PMID:
9262315
16.

Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant human A1 receptor.

Kollias-Baker CA, Ruble J, Jacobson M, Harrison JK, Ozeck M, Shryock JC, Belardinelli L.

J Pharmacol Exp Ther. 1997 May;281(2):761-8.

PMID:
9152383
17.

Heat stress protects the perfused rabbit heart from complement-mediated injury.

Gralinski MR, Black SC, Stancato LF, Kilgore KS, Campau PA, Park JL, Ozeck MJ, Pratt WB, Lucchesi BR.

Am J Physiol. 1996 Aug;271(2 Pt 2):H571-8.

PMID:
8770098

Supplemental Content

Support Center